Loading
Chronic Lymphocytic Leukemia Research · Journal article
Eye & Contact Lens Science & Clinical Practice · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of a 73-year-old woman receiving zanubrutinib for mantle cell lymphoma who developed corneal infection with Moraxella nonliquefaciens preceded by three months of bilateral ocular surface disease. The authors propose zanubrutinib as a potential cause of ocular surface dysfunction predisposing to secondary infection, but the evidence is observational and descriptive without quantification of risk or comparison to unexposed patients.
Case report. A 73-year-old woman treated with zanubrutinib for mantle cell lymphoma presenting with acute ocular pain and decreased vision; no prior ocular disease history.. Intervention: Zanubrutinib for mantle cell lymphoma; topical antimicrobial therapy and topical corticosteroids for ocular disease.
Patient presented with acute corneal epithelial defect and stromal infiltrate with positive corneal culture for Moraxella nonliquefaciens Three months of bilateral ocular irritation and conjunctival hyperemia preceded acute infectious episode Bilateral epithelial surface abnormalities and microcystic changes observed on slitlamp examination
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This report alerts ophthalmologists to the possibility of ocular surface toxicity as an emerging adverse effect of zanubrutinib, warranting increased vigilance during treatment. However, a single case cannot establish causation or incidence, and further systematic investigation is required to determine whether this is a true drug effect or coincidental occurrence.
A single case report raising a novel hypothesis about zanubrutinib-associated ocular surface dysfunction; descriptive rather than comparative, with no control group or quantified incidence.
As stated by the source record.
Quoted from the source exactly as published.
This report alerts ophthalmologists to the possibility of ocular surface toxicity as an emerging adverse effect of zanubrutinib, warranting increased vigilance during treatment. However, a single case cannot establish causation or incidence, and further systematic investigation is required to determine whether this is a true drug effect or coincidental occurrence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT: Zanubrutinib, a second-generation Bruton tyrosine kinase inhibitor used in B-cell malignancies, has a favorable systemic safety profile, whereas its ocular surface effects remain insufficiently defined. We report a 73-year-old woman receiving zanubrutinib for mantle cell lymphoma who presented with acute pain and decreased vision in the right eye. Slitlamp examination revealed a corneal epithelial defect with an associated stromal infiltrate in the right eye and bilateral epithelial surface abnormalities. The patient reported three months of bilateral ocular irritation and conjunctival hyperemia before this acute presentation. Corneal cultures grew Moraxella nonliquefaciens. Topical antimicrobial therapy resulted in resolution of the infiltrate. However, ongoing bilateral epithelial instability with microcystic changes required adjunctive topical corticosteroids, leading to substantial clinical improvement. The prolonged bilateral prodrome preceding the acute infectious episode, together with the absence of prior ocular disease, raises concern for zanubrutinib-associated ocular surface dysfunction predisposing to secondary infection. To the best of our knowledge, this is the first report suggesting an association between zanubrutinib therapy and corneal surface disease. This case raises a potential ocular side effect of zanubrutinib, emphasizing the need for further investigation. As immunotherapy use expands, ophthalmologists should remain vigilant for emerging ocular toxicities and collaborate with oncology specialists for optimal patient care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.